Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grissom, C. K.
Right arrow Articles by Elstad, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grissom, C. K.
Right arrow Articles by Elstad, M. R.
(Chest. 2005;127:565-570.)
© 2005 American College of Chest Physicians

The Effects of a 5-Lipoxygenase Inhibitor on Acute Mountain Sickness and Urinary Leukotriene E4 After Ascent to High Altitude*

Colin K. Grissom, MD, FCCP; Lori D. Richer, MD and Mark R. Elstad, MD

* From the Pulmonary and Critical Care Division (Dr. Grissom), Department of Medicine, LDS Hospital, Salt Lake City, UT; Dartmouth Family Practice Residency (Dr. Richer), Concord Hospital, Concord, NH; and Department of Veteran’s Affairs Medical Center (Dr. Elstad), Salt Lake City, UT.

Correspondence to: Colin K. Grissom, MD, FCCP, Pulmonary Division, LDS Hospital, Eighth Ave and C St, Salt Lake City, UT 84143; e-mail: LDCGRISS{at}ihc.com

Background: Elevated urine and blood leukotriene levels have been reported after ascent to high altitude in association with acute mountain sickness (AMS) and high-altitude pulmonary edema. Zileuton is an inhibitor of the enzyme 5-lipoxygenase that catalyzes conversion of arachidonic acid to leukotrienes.

Study objectives and design: The objectives of this randomized, double-blind, placebo-controlled clinical trial were to determine whether zileuton (600 mg po qid) is effective prophylaxis for AMS, and to measure the effect of ascent to high altitude and zileuton on urinary leukotriene E4 levels.

Setting and participants: The study group consisted of volunteers from among climbers on the West Buttress of Mt. McKinley (Denali), Alaska. After baseline urine samples at sea level, subjects flew by airplane to 2,300 m, and then ascended to the 4,200-m camp in 5 to 10 days.

Measurements and results: Using an enzyme immunoassay, urinary leukotriene E4 was found to decrease after ascent to high altitude in both the zileuton and placebo groups. Urinary leukotriene E4 in the zileuton group (n = 9) decreased from 67 ± 35 pg/mg creatinine at sea level to 33 ± 22 pg/mg creatinine at high altitude (p = 0.003) [mean ± SD]. Urinary leukotriene E4 in the placebo group (n = 9) decreased from 97 ± 82 pg/mg creatinine at sea level to 44 ± 21 pg/mg creatinine at high altitude (p = 0.045). One subject in the zileuton group and three subjects in the placebo group met Lake Louise criteria for AMS after arriving at 4,200 m (p = 0.257).

Conclusions: Elevated leukotrienes are not associated with ascent to high altitude. In subjects with AMS, urinary leukotrienes were not elevated, suggesting that leukotrienes may not be a component of the pathophysiology of AMS. The low incidence of AMS and the small sample size in this study prevented determination of whether zileuton is effective prophylaxis for AMS.

Key Words: acute mountain sickness • high altitude • urinary leukotriene E4 • zileuton






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American College of Chest Physicians.